Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nanobiotix ( (NBTX) ) just unveiled an announcement.
On July 7, 2025, Nanobiotix announced significant regulatory and intellectual property advancements for its potential first-in-class radioenhancer, JNJ-1900 (NBTXR3). The product has been reclassified from a medical device to a medicinal product in major European countries, aligning its status with the US and other markets, which supports a unified global regulatory strategy. Additionally, a new composition of matter patent has been filed to strengthen its intellectual property. These developments are expected to enhance the global positioning of JNJ-1900, which is undergoing a comprehensive clinical development program, including a pivotal Phase 3 trial in head and neck cancer.
The most recent analyst rating on (NBTX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall score is significantly impacted by its poor financial performance, characterized by negative profitability and cash flows, and a weak balance sheet. While technical analysis shows positive momentum, the valuation remains unattractive due to negative earnings, limiting the stock’s appeal.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, with a focus on pioneering physics-based therapeutic approaches to improve treatment outcomes for cancer patients. The company is listed on Euronext Paris and Nasdaq, and it holds over 25 umbrella patents across three nanotechnology platforms, including oncology, bioavailability and biodistribution, and central nervous system disorders.
Average Trading Volume: 8,429
Technical Sentiment Signal: Buy
Current Market Cap: $257.7M
See more insights into NBTX stock on TipRanks’ Stock Analysis page.